Glaukos Corporation stocks have been trading up by 18.7 percent after positive glaucoma treatment trial data boosted investor optimism.
Click Here for a Millionaire's POV on Trading GKOS
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Q1 results from GKOS topped expectations, with revenue at $150.6M vs. $137.0M and a narrower loss, showcasing strong traction for iDose TR and Epioxa.
- Management at Glaukos guided 2026 revenue to $620M–$635M, modestly ahead of Street models around $613M–$614M and above prior company targets.
- A new permanent CMS J-code for Epioxa, effective 2026/07/01, should streamline reimbursement and support wider U.S. access over time.
- Citi bumped its GKOS price target to $135 from $125 and reiterated a Buy, despite broader med‑tech multiple pressure.
- Glaukos’ latest Sustainability Report spotlights ESG work, Alabama R&D/manufacturing expansion, and prep for the 2026 Epioxa commercial launch.
Live Update At 12:32:36 EDT: On Thursday, April 30, 2026 Glaukos Corporation stock [NYSE: GKOS] is trending up by 18.7%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
The recent tape tells you exactly why traders are locked in on GKOS. Over the last few weeks, Glaukos Corporation has pushed from the low $110s to a spike high above $145, with the latest close around $138.86. That’s a big expansion after Q1 numbers hit on 2026/04/29 and confirmed the growth story.
Revenue for Glaukos over the last year sits around $507.4M, growing more than 20% annually over three and five years. Profitability is still in the red — margins are roughly -37% at the bottom line — but gross margin is a healthy 55.7%. That tells traders GKOS spends heavily on R&D and commercialization, not that the core products are weak.
The balance sheet for Glaukos backs that view up. Debt levels are low, with total debt-to-equity around 0.16 and a current ratio near 4.7, giving GKOS room to ride out volatility. Cash and short-term investments near $279M reinforce that cushion. The valuation is rich, with price-to-sales about 13.8 and price-to-book above 10, so this is a momentum and growth name, not a value setup. For active traders, that combination — strong top-line growth, ample liquidity, but ongoing losses — often fuels big trend moves once catalysts hit.
More Breaking News
- RVMD Stock Climbs As Daraxonrasib Data Ignite Street Targets
- ONDS Stock Builds Defense Backlog As Analysts Turn Bullish
- Nokia Stock Jumps As Analysts Hike Price Targets On AI Boom
- RMAX Stock Pops As Housing Rebounds And Productivity Shines
Intraday, GKOS is trading like a momentum name. On the latest session, Glaukos gapped up, flushed hard to an intraday low near $130.90, then ripped back into the high $130s and held that area. That kind of wide range shows aggressive dip buyers stepping into GKOS on volatility, a key tell for short-term trading setups.
Why Traders Are Watching GKOS Right Now
Glaukos has given traders a clean catalyst stack, and the price action is reacting in textbook fashion. The first driver is the Q1 earnings beat. GKOS printed revenue of $150.6M versus $137.0M expected and an EPS loss of -$0.18 versus -$0.28 consensus. For a high‑growth med‑tech like Glaukos, narrowing losses while outrunning revenue estimates is exactly what momentum traders want to see. It signals that iDose TR and Epioxa are not just science stories — they are selling.
Right after that, Glaukos raised its 2026 revenue outlook to $620M–$635M. That’s above previous guidance and comfortably above Street expectations in the low $613M range. When a company like GKOS is already trading at a premium multiple, traders need forward numbers to move higher, not lower. This is guidance revision in the right direction.
The CMS permanent J-code for Epioxa is the second key catalyst. Effective 2026/07/01, that code should streamline billing and reimbursement for the keratoconus therapy. For traders, the code means fewer barriers when Epioxa launches broadly in the U.S., which strengthens the long runway Glaukos is pitching.
Layer on top Citi’s price target hike on GKOS to $135 from $125, with a maintained Buy rating. In a med‑tech sector facing multiple compression, seeing a major bank step up for Glaukos positions GKOS as a relative strength story. Add upcoming exposure at the 2026 ASCRS meeting, where Glaukos will showcase Epioxa, iDose TR, and iStent infinite, and you get a multi‑product narrative. That’s important because traders want to know GKOS is not a one‑drug wonder but a platform ophthalmology name with depth.
Finally, Glaukos highlighted ESG progress and capacity expansion in Alabama in its 2025 Sustainability Report. While ESG rarely drives day‑trades, it does signal that GKOS is building infrastructure behind the growth, which longer‑term capital often respects. For short‑term trading, those structural moves support the idea that strong quarters are not one‑off.
Conclusion
For active traders dissecting GKOS, the story right now is clear: strong execution, rising guidance, and a reimbursement win lining up ahead of a major product ramp. Glaukos delivered a Q1 beat on both revenue and EPS, showing that iDose TR and Epioxa are scaling into real businesses, not just pipeline hopes. The market is rewarding that with higher prices and heavy ranges, which is exactly where trading opportunity lives.
At the same time, the fundamentals underneath GKOS remain those of an aggressive growth name. Glaukos is still unprofitable, trading at a high price-to-sales ratio, and leaning hard into R&D and commercialization spend. That mix means GKOS can move fast in both directions. Traders who chase without a plan risk getting run over when volatility spikes. This is where trading discipline and price action focus really matter. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.” That mindset is crucial when you’re reacting to GKOS’s sharp moves rather than forcing a bias onto the chart.
The CMS J-code, the higher 2026 revenue guide, and Citi’s target bump all lean bullish for Glaukos over the medium term, but disciplined execution in trading GKOS still matters more than any single headline. As Tim Sykes likes to say, “Patterns repeat, but only traders who study and stick to rules are ready when they do.” With Glaukos, the pattern on the tape is strong growth plus strong momentum — and traders who respect both the upside and the risk will be the ones who stay in the game.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.